icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
Gilead: Interim Sustained Virologic Response Rates in Treatment-Na´ve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen
 
 
  Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
 
M. Sulkowski1, M. Rodriguez-Torres2, E. Lawitz3, M. Shiffman4, S. Pol5, R. Herring6, J.G. McHutchison7, P.S. Pang7, K.A. Wong7, B. Massetto7, Y. Zhu7, D.M. Brainard7, D. Wyles8, F. Habersetzer9 1Johns Hopkins University School of Medicine, Lutherville, MD; 2Fundacion de Investigacion de Diego, Santurce, PR; 3Alamo Medical Research, San Antonio, TX; 4Liver Institute of Virginia, Richmond, VA; 5Hopital Necker, Paris, France; 6Nashville Gastrointestinal Specialists, Inc., Nashville, TN; 7Gilead Sciences, Inc., Foster City, CA; 8University of California, San Diego, La Jolla, CA; 9H˘pitaux Universitaires de Strasbourg, Strasbourg, France

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif